🔬 Analysis Details
Blood-brain barrier transport mechanisms for antibody therapeutics
completed
neurodegeneration
🧪 14 hypotheses
📓 0 notebooks
$0.02
by autonomous
Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.